Liver Disease Clinical Trials in Dallas, TX

66 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )	Phase 3	Inventiva Pharma	<1 mi
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis	Phase 3	Boehringer Ingelheim	<1 mi
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis	Phase 3	Boehringer Ingelheim	<1 mi
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition	Phase 2	Regeneron Pharmaceuticals	<1 mi
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis	Phase 3	Ipsen	<1 mi
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)	Phase 2	Boehringer Ingelheim	<1 mi
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection	Phase 2	Gilead Sciences	<1 mi
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH	Phase 3	Akero Therapeutics, Inc	<1 mi
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma	Phase 3	Children's Oncology Group	<1 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease	Phase 2	GlaxoSmithKline	<1 mi
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor	Phase 1/2	Eisai Inc.	<1 mi
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment	—	Ipsen	<1 mi
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation	—	University of Alberta	<1 mi
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk	Phase 2	Raymond Chung	<1 mi
A-LiNK: Improving Outcomes in Autoimmune Liver Disease	—	Children's Hospital Medical Center, Cincinnati	<1 mi
The Hepatitis C Transplant Collaborative	—	Baylor Research Institute	<1 mi
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis	Phase 2	Mirum Pharmaceuticals, Inc.	<1 mi
TReatment for ImmUne Mediated PathopHysiology	Phase 2	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	<1 mi
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs	—	European Foundation for Study of Chronic Liver Failure	<1 mi
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)	N/A	Perspectum	<1 mi
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome	Phase 3	Albireo, an Ipsen Company	<1 mi
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study	Phase 2	Intercept Pharmaceuticals	<1 mi
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics	Phase 1	PharmaIN	<1 mi
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis	Phase 3	Gilead Sciences	<1 mi
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population	—	Methodist Health System	<1 mi
A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center	—	Methodist Health System	<1 mi
Functional Assessment in Liver Transplantation	—	University of California, San Francisco	<1 mi
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)	Phase 2	Altimmune, Inc.	<1 mi
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial	Phase 2	Samer Gawrieh	<1 mi
Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement	N/A	Methodist Health System	<1 mi
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)	—	Target PharmaSolutions, Inc.	<1 mi
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)	N/A	VA Office of Research and Development	<1 mi
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)	Phase 3	Bausch Health Americas, Inc.	<1 mi
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)	Phase 4	Camille N. Kotton, MD	<1 mi
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment	—	Ipsen	<1 mi
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)	Phase 2	Deciphera Pharmaceuticals, LLC	<1 mi
T-Cell Therapy (ECT204) in Adults With Advanced HCC	Phase 1/2	Eureka Therapeutics Inc.	<1 mi
EGCG for Hepatocellular Carcinoma Chemoprevention	Phase 2	University of Texas Southwestern Medical Center	<1 mi
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial	Phase 3	ECOG-ACRIN Cancer Research Group	<1 mi
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	Phase 1/2	Tvardi Therapeutics, Incorporated	<1 mi
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer	—	National Cancer Institute (NCI)	<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	—	Massive Bio, Inc.	<1 mi
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)	Phase 2	Daiichi Sankyo	<1 mi
National Liver Cancer Screening Trial	Phase 4	University of Texas Southwestern Medical Center	<1 mi
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules	N/A	University of Texas Southwestern Medical Center	<1 mi
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis	Phase 2	Genentech, Inc.	<1 mi
Evaluation of Resection Techniques for Pancreatic Tumors	—	Methodist Health System	<1 mi
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors	Phase 1	Conjupro Biotherapeutics, Inc.	<1 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	Phase 3	AstraZeneca	<1 mi
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma	Phase 1	Alnylam Pharmaceuticals	<1 mi
DESTINY-PANTUMOUR04	—	AstraZeneca	<1 mi
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)	Phase 2/3	AbbVie	<1 mi
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers	Phase 1	Pilatus Biosciences Inc	<1 mi
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer	Phase 2	AstraZeneca	<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy	Phase 3	Pierre Fabre Medicament	<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors	Phase 1	Exelixis	<1 mi
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years	Phase 4	Guerbet	<1 mi
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis	Phase 3	Can-Fite BioPharma	<1 mi
Ligufalimab and Cadonilimab in Advanced Liver Cancers	Phase 2	University of Texas Southwestern Medical Center	<1 mi
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	Phase 3	Eli Lilly and Company	12 mi
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)	Phase 3	89bio, Inc.	12 mi
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH	Phase 3	89bio, Inc.	12 mi
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)	Phase 2	Eccogene	12 mi
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)	Phase 3	Mirum Pharmaceuticals, Inc.	25 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.